Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365530 | 0.80 | GAA (0.50) | GAANPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL14962838 | 0.80 | CA12 (0.51) | CA12CA14CA2GAAKDM4E | |
| SCHEMBL8930152 | 0.78 | CA12 (0.48) | CA12CA14CA2TET2GAA | |
| SCHEMBL2583703 | 0.78 | CA12 (0.48) | CA12CA14CA2TET2GAA | |
| SCHEMBL25039078 | 0.77 | CA12 (0.53) | CA12CA14CA2TET2GAA | |
| SCHEMBL22475391 | 0.76 | CA12 (0.47) | CA12CA14CA2TET2GAA | |
| SCHEMBL15592453 | 0.76 | CA12 (0.47) | CA12CA14CA2TET2GAA | |
| SCHEMBL4674334 | 0.76 | CA12 (0.47) | CA12CA14CA2TET2GAA | |
| SCHEMBL10667453 | 0.76 | CA12 (0.47) | CA12CA14CA2TET2GAA | |
| SCHEMBL22345253 | 0.74 | CA12 (0.42) | CA12CA14CA2TET2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203586-B2 | Iridinesulfonamide compound and use method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-21 | — | — | US | disclosed |
| US-11203586-B2 | Iridinesulfonamide compound and use method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-21 | — | — | US | disclosed |
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20210155610-A1 | Iridinesulfonamide Compound And Use Method Thereof | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210155610-A1 | Iridinesulfonamide Compound And Use Method Thereof | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| CN-109071429-B | Prophyridine sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3444237-B1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3444237-B1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-09-26 | — | — | US | disclosed |
| EP-3444237-A1 | IRIDINESULFONAMIDE COMPOUND AND USE METHOD THEREOF | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| US-9073906-B2 | Sulfamide derivative having an adamantyl group and its pharmaceutically acceptable salt | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-07-07 | — | — | US | disclosed |
| CN-104080766-A | Sulphamide derivative having an adamantyl group and a pharmaceutically acceptable salt thereof | KOREA RES INST CHEM TECH | 2014-10-01 | — | — | CN | disclosed |
| EP-2740723-A2 | SULPHAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Korea Research Institute of Chemical Technology (KR) | 2014-06-11 | — | — | EP | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-01-23 | — | — | US | disclosed |
| EP-1137640-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6281363-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; AUTOIMMUNE DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-08-28 | — | — | US | disclosed |
| WO-2000035885-A1 | CYCLIC HYDRAZINE DERIVATIVES AS TNF-ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| US-5596017-A | INSECTICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1997-01-21 | — | — | US | disclosed |
| EP-0684229-A1 | Sulfamide derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203586-B2 | Iridinesulfonamide compound and use method thereof | IDH1, IDH3B, IDH3A | CA12 806/4885CA14 802/4885CA2 427/4885 |
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CA12 2596/4885CA14 3112/4885CA2 1506/4885 |
| US-20140024636-A1 | SULFAMIDE DERIVATIVE HAVING AN ADAMANTYL GROUP AND ITS PHARMACEUTICALLY ACCEPTABLE SALT | HSD11B1, HSD11B2, HSD3B1 | CA12 838/4885CA14 836/4885CA2 1279/4885 |
| US-20210155610-A1 | Iridinesulfonamide Compound And Use Method Thereof | IDH1, IDH3B, IDH3A | CA12 806/4885CA14 802/4885CA2 427/4885 |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | CA12 2596/4885CA14 3112/4885CA2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.